Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN 3 5 W DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN 3 5 W DEXTROSE 5 IN PLASTIC CONTAINER.
AMINOSYN 3.5% M IN PLASTIC CONTAINER vs AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
Aminosyn 3.5% w/ Dextrose 5% provides essential and non-essential amino acids for protein synthesis and dextrose for caloric support, aiding in nitrogen balance and maintenance of lean body mass in parenteral nutrition.
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
Intravenous infusion. Adult dose: 500-1000 mL per day, infused at a rate not exceeding 100 mL/hour, adjusted based on metabolic requirements and tolerance.
None Documented
None Documented
Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids.
Not applicable as a single entity; amino acids and dextrose are endogenous substances. Metabolic half-life of infused amino acids ~10-30 min; dextrose ~15-20 min. Continuous infusion results in steady state.
Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination.
Renal excretion of amino acids and dextrose metabolites (CO2, water). Urea nitrogen accounts for ~80-90% of nitrogen excretion. Unchanged dextrose minimal (<1%). Biliary/fecal excretion negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution